SAN CARLOS, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in a phase 2 clinical trial of AKST4290, an orally administered CCR3 inhibitor, for treatment of Parkinson?s disease. The trial, AKST4290-211?(TEAL),?is?funded in part by The Michael J. Fox Foundation for Parkinson?s Research (MJFF) and will evaluate the effect of AKST4290 on motor function and activities of daily living in patients with Parkinson?s disease.? ? ? ? ? ? ? ? ? ? ? ??